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Abstract
Background: The effect of statin therapy on mortality in critically ill patients is controversial, with some studies
suggesting a benefit and others suggesting no benefit or even potential harm. The objective of this study was to
evaluate the association between statin therapy during intensive care unit (ICU) admission and all-cause mortality
in critically ill patients.
Methods: This was a nested cohort study within two randomised controlled trials conducted in a tertiary care ICU.
All 763 patients who participated in the two trials were included in this study. Of these, 107 patients (14%)
received statins during their ICU stay. The primary endpoint was all-cause ICU and hospital mortality. Secondary
endpoints included the development of sepsis and severe sepsis during the ICU stay, the ICU length of stay, the
hospital length of stay, and the duration of mechanical ventilation. Multivariate logistic regression was used to
adjust for clinically and statistically relevant variables.
Results: Statin therapy was associated with a reduction in hospital mortality (adjusted odds ratio [aOR] = 0.60, 95%
confidence interval [CI] 0.36-0.99). Statin therapy was associated with lower hospital mortality in the following
groups: patients >58 years of age (aOR = 0.58, 95% CI 0.35-0.97), those with an acute physiology and chronic
health evaluation (APACHE II) score >22 (aOR = 0.54, 95% CI 0.31-0.96), diabetic patients (aOR = 0.52, 95% CI 0.30-
0.90), patients on vasopressor therapy (aOR = 0.53, 95% CI 0.29-0.97), those admitted with severe sepsis (aOR =
0.22, 95% CI 0.07-0.66), patients with creatinine ≤100 μmol/L (aOR = 0.14, 95% CI 0.04-0.51), and patients with GCS
≤9 (aOR = 0.34, 95% CI 0.17-0.71). When stratified by statin dose, the mortality reduction was mainly observed with
statin equipotent doses ≥40 mg of simvastatin (aOR = 0.53, 95% CI 0.28-1.00). Mortality reduction was observed
with simvastatin (aOR = 0.37, 95% CI 0.17-0.81) but not with atorvastatin (aOR = 0.80, 95% CI 0.84-1.46). Statin
therapy was not associated with a difference in any of the secondary outcomes.
Conclusion: Statin therapy during ICU stay was associated with a reduction in all-cause hospital mortality. This
association was especially noted in high-risk subgroups. This potential benefit needs to be validated in a
randomised, controlled trial.
Background
Statins, also known as 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors, were first introduced in
the late 1980s as cholesterol-lowering drugs for the pre-
vention of cardiovascular events. However, recent stu-
dies have demonstrated a wide variety of statin
properties independent of their lipid-lowering ability.
These properties, known as pleiotropic effects [1-4],
include multiple anti-inflammatory actions, the direct
activation of heme oxygenase, direct interference in leu-
cocyte-endothelial interactions, and direct inhibition of
major histocompatibility complex class II (MHC II)
[5-10].
The effect of statin therapy on mortality in critically ill
patients is controversial, with some studies suggesting a
benefit and others no benefit or even potential harm
[11-17]. These divergent results are probably related to
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[4,11-14,18,19], statin types, and doses [4,15,17,20].
Therefore, we sought to evaluate the association of sta-
tin therapy during the intensive care unit (ICU) stay




This study was conducted in a 900-bed tertiary aca-
demic medical centre. The adult ICU admits medical,
surgical, and trauma patients, and it operates as a closed
unit with 24-hr, 7-day onsite coverage by a critical care
board of certified intensivists. The nurse-to-patient ratio
at the unit is approximately 1:1.2 [21].
Study design
This was a nested cohort study within two randomised,
controlled trials.
The first trial, conducted between January 2004 and
March 2006 included 532 patients, compared intensive
insulin therapy (IIT) (for patients with a blood glucose
level of 4.4-6.1 mmol/L or 80-110 mg/dl) to conventional
insulin therapy (CIT) (for patients with a blood glucose
level of 10-11.1 mmol/L or 180-200 mg/dl) [22]. This trial
showed no significant difference in ICU mortality between
the IIT and CIT groups (13.5% vs. 17.1%, p = 0.3). Hypo-
glycemia occurred more frequently in the IIT than in the
CIT group (28.6% vs. 3.1% of patients; p < 0.0001) [22].
The second trial, conducted between February 2006
and January 2008, included 240 patients and assessed
the effects on outcomes of permissive underfeeding (a
caloric goal of 60-70% of the calculated requirement)
versus target feeding (caloric goal of 90-100% of the cal-
culated requirement) with either IIT or CIT in critically
ill patients [23]. The study found no difference between
the two groups in 28-day mortality (18% vs. 23%, p =
0.34). However, hospital mortality was lower in the per-
missive underfeeding compared with the target-feeding
group (30% vs. 43%, p = 0.04) [23]. All patients enrolled
in the original two trials were included in this study.
Statin therapy
Statins for critically ill patients were prescribed as part
of the medication reconciliation process if they had
been prescribed in the pre-ICU period. Occasionally,
statin therapy was initiated in the ICU for patients
admitted with acute coronary syndrome or stroke. The
prescribed dose was at the discretion of the treating
physician. Data regarding the use, type (simvastatin or
atorvastatin) and dose of statin were collected from the
hospital information system. Doses of atorvastatin were
converted into the equivalent dose of simvastatin at a
atorvastatin: simvastatin ratio of 1:2.
Data Collection
Patient outcomes and the following data were retrieved
from the two original studies: age, gender, acute physiol-
ogy and chronic health evaluation (APACHE II) score
[24], sequential organ failure assessment (SOFA) score
[25], creatinine, platelet count, bilirubin, international
normalised ratio (INR), Glasgow coma scale (GCS)
score [26], admission category, history of diabetes, need
for mechanical ventilation, vasopressor therapy, sepsis,
severe sepsis and septic shock and the presence of
chronic cardiac, respiratory, renal, hepatic, or immuno-
compromising diseases, as defined by the APACHE II
system [24].
Outcomes
The primary outcomes were all-cause ICU and hospital
mortality. Secondary outcomes included the develop-
ment of sepsis and severe sepsis during the ICU stay,
ICU and hospital length of stay, and the duration of
mechanical ventilation. Sepsis and severe sepsis were
defined according to the 2001 International Sepsis Defi-
nitions Conference [27]. The two trials were approved
by the research committee and institutional review
board of King Abdulaziz Medical City.
Statistical analysis
Statistical analyses were performed using Statistical Ana-
lysis Software (SAS, release 8, SAS Institute, Cary, NC,
1999). We compared patients who received statins dur-
ing their ICU admission (statin group) with those who
did not (non-statin group). Baseline characteristics and
outcome variables were compared using t-test for con-
tinuous data and Chi-square test for nominal data. To
control for any potential confounding effects of baseline
characteristics, we used multiv a r i a t el o g i s t i cr e g r e s s i o n
to calculate adjusted odds ratios (aOR) and 95% confi-
dence intervals (CI) for the association between statin
use and outcome. Adjustments were made for clinically
relevant variables and for those that showed a statisti-
cally significant difference between the two groups at
baseline. These variables included age, gender, admis-
sion category, APACHE II score, history of diabetes,
creatinine, platelets, GCS,a n dt h ep r e s e n c eo fc h r o n i c
cardiac, renal, or respiratory diseases. We further exam-
ined the dose effects of statins on the primary and sec-
ondary outcomes by stratifying patients on the basis of
doses equivalent to <40 mg and ≥ 40 mg of simvastatin.
Additionally, we conducted stratified analyses by age,
gender, admission category, APACHE II score, history
of diabetes, the presence of chronic cardiac problems,
vasopressor therapy, sepsis, severe sepsis and septic
shock, creatinine, platelet count, bilirubin, INR, GCS,
ICU length of stay, mechanical ventilation and type of
statin, to detect any change in the association between
Al Harbi et al. BMC Clinical Pharmacology 2011, 11:12
http://www.biomedcentral.com/1472-6904/11/12
Page 2 of 7intervention and outcome measures on the basis of any
of these factors. Statistical significance was defined as a
p value ≤ 0.05.
Results
Of the 763 patients enrolled in the study, 107 (14%)
received statins during their ICU stay, and 656 (86%)
did not. Atorvastatin was prescribed to 63 patients
(58.9%), with doses ranging between 10 and 80 mg/day.
Simvastatin was prescribed to 44 patients (41.1%), with
doses ranging between 10 and 40 mg/day. Table 1 com-
pares the baseline characteristics of the statin and non-
statin groups. Patients who received statins were older;
more likely to be females; diabetic; more likely to have
chronic cardiac, renal or respiratory illness; and had
higher APACHE II scores.
Table 2 summarises the association between statin
therapy and mortality using multivariate analysis adjust-
ing for the selected confounders. Statin therapy was
associated with lower all-cause hospital mortality (aOR
= 0.60, 95% CI 0.36-0.99). The association between sta-
tins and ICU mortality was not statistically significant
(aOR = 0.84, 95% CI 0.47-1.51). When stratified by sta-
tin dose, a significant reduction in hospital mortality
was observed with doses of ≥40 mg (aOR = 0.53, 95%
CI 0.28-1.00).
Table 3 shows the association between statin therapy
and all-cause hospital mortality stratified by different
characteristics using multivariate analysis. Statin therapy
was associated with lower hospital mortality in patients
older than 58 years (aOR = 0.58, 95% CI 0.35-0.97),
those with an APACHE II score >22 (aOR = 0.54, 95%
CI 0.31-0.96), diabetic patients (aOR = 0.52, 95% CI
0.30-0.90), patients on vasopressor therapy (aOR = 0.53,
95% CI 0.29-0.97), those with creatinine ≤100 μmol/L
(aOR = 0.14, 95% CI 0.04-0.51), patients with severe
sepsis (aOR = 0.22, 95% CI 0.07-0.66), and patients with
aG C S≤ 9 (aOR = 0.34, 95% CI 0.17-0.71). When strati-
fied by statin type, statistically significant association
with lower mortality was observed by simvastatin (aOR
= 0.37, 95% CI 0.17-0.81), but not with atorvastatin.
There was no significant association between statin
use and the development of sepsis or severe sepsis and
septic shock, ICU and hospital length of stay, or the
duration of mechanical ventilation (Table 4).
Discussion
Our study demonstrates that statin therapy in critically
ill patients is associated with lower hospital mortality.
This effect was observed predominantly in elderly
patients, diabetics, patients with higher severity of ill-
n e s s ,w i t hal o wG C S ,p a t i e n t so nv a s o p r e s s o r s ,w i t h
severe sepsis, and those on simvastatin.
Several studies have shown favourable effects of statin
therapy on outcomes in critically ill patients. Liappies et
al. retrospectively reviewed patients with documented
bacteraemia and found that statin therapy was asso-
ciated with a significant reduction in overall hospital
mortality and infection rates (11). Almog et al. found
that prior statin therapy was associated with a reduction
in severe sepsis and the incidence of ICU admission
[12]. Kruger et al. studied a cohort of bacteraemia
patients and found a significantly lower incidence of
mortality and bacteraemia-related mortality with statin
therapy [13]. Mortensen et al. found that statin therapy
before ICU admission was associated with a decreased
30-day mortality [20]. A recent systematic review exam-
ined the effect of statins on mortality in patients with
infection and/or sepsis. The review included a total of
20 studies, with 18 cohort studies (12 retrospective and
6 prospective), 1 matched cohort study with 2 case-con-
trolled studies, and 1 randomised, controlled trial. The
review demonstrated a protective effect of statin therapy
for various infection-related outcomes compared with
placebo in patients with sepsis and/or other infections
[28]. These studies are in concordance with ours, which
Table 1 Baseline characteristics of patients on statin






Age, mean ± SD (yrs) 68.8 ± 11.0 49.3 ± 21.7 < 0.0001
Female gender, no. (%) 44 (41.1) 164 (25) 0.0005
APACHE II, mean ± SD 27.2 ± 6.9 23.0 ± 8.1 < 0.0001
SOFA day 1, mean ± SD 9.3 ± 3.2 9.2 ± 3.5 0.92
Creatinine, mean ± SD,
μmol/L*
200.8 ± 152.6 152.3 ± 152.1 0.002
Platelets, mean ± SD, x10
9/L 270.7 ± 117.8 193.3 ± 123.3 0.0001
Bilirubin, mean ± SD, μmol/l 26.4 ± 63.6 31.6 ± 55.2 0.50
INR, mean ± SD 1.5 ± 0.7 1.5 ± 0.9 0.72
GCS, mean ± SD 9.4 ± 4.5 8.5 ± 4.0 0.05
ICU admission category, no. (%)
Postoperative 4 (3.7) 119 (18.1) 0.0002
Nonoperative 103 (96.3) 537 (81.9)
History of diabetes, no. (%) 84 (78.5) 219 (33.4) < 0.0001
Mechanically ventilated, no. (%) 92 (86.0) 591 (90.1) 0.20
Vasopressors, no. (%) 73 (68.2) 423 (64.5) 0.45
Sepsis, no. (%) 28 (26.2) 166 (25.3) 0.85
Severe sepsis, no. (%) 26 (24.3) 207 (31.5) 0.13
Chronic respiratory, no. (%) 33 (30.8) 124 (18.9) 0.005
Chronic cardiac, no. (%) 54 (50.5) 103 (15.7) < 0.0001
Chronic renal, no. (%) 29 (27.1) 74 (11.3) < 0.0001
Chronic liver, no. (%) 4 (3.7) 50 (7.6) 0.15
Chronic immunocompromised,
no. (%)
10 (9.4) 56 (8.5) 0.78
SD: standard deviation, APACHE II: Acute physiology and chronic health
evaluation II; SOFA: Sequential organ failure assessment; INR: International
normalised ratio; GCS: Glasgow coma scale.
*To convert units to mg/dl, divide by 88.4 for creatinine and 17.1 for bilirubin
Al Harbi et al. BMC Clinical Pharmacology 2011, 11:12
http://www.biomedcentral.com/1472-6904/11/12
Page 3 of 7demonstrated a significant reduction in mortality with
statin therapy in critically ill patients and patients with
sepsis, severe sepsis and septic shock. The effect was
primarily observed with higher doses of statins.
In contrast, some investigators have not found statin
therapy to be beneficial. Fernandez et al. analysed data
from 438 patients receiving mechanical ventilation for
more than 96 hr and found that hospital mortality was
significantly higher with statin therapy (61% vs. 42%),
even after adjusting for APACHE II predicted risk
(observed/expected ratio 1.53 vs. 1.17). In a population-
based study of community-acquired pneumonia,
Majumdar et al. found that statin users were less likely
to die or to be admitted to the ICU than non-users (50/
325 [15%] vs. 574/3090 [19%], respectively; OR 0.80, p =
0.15). However, after a more complete adjustment for
confounding factors, the OR changed from potential
benefit (0.78, adjusted for age and sex) to potential
harm (1.10, fully adjusted, including propensity scores,
95% CI 0.76-1.60). This disagreement with the findings
of our study may be explained by differences in illness
severity. As subjects of a population-based study, the
patients of Majumdar et al. were relatively healthy users
[15] compared with our population. Additionally, it
remains unclear whether these findings, which were
observed in patients with community-acquired pneumo-
nia, are applicable to all critically ill patients. Yang et al.
conducted a retrospective study and found no difference
in mortality between the two groups, despite the pre-
sence in patients in the statin group of less organ dys-
function, lower APACHE II scores, less inotropic
support, and less shock [16]. The lack of benefit
observed in these studies might be related to differences
in the patient disease mix, severity of illness, or statin
type/dose.
Our study demonstrated a mortality reduction in older
patients and those with more severity of illness. This
result confirms what other previous studies have shown.
Dobesh et al. evaluated patients over the age of 40 with
severe sepsis who were exposed to statins before and/or
during hospitalisation. The mean APACHE II score in
the statin group was 26. Patients in the statin group
showed a lower mortality compared with the no statin
group (31.7% vs. 48.4%; p = 0.04), and this effect was
more evident in older patients and those with higher
APACHE II score [18]. Schmidt et al. evaluated statin
therapy in patients with multi-organ dysfunction and a
mean APACHE II score ≥ 30. The study demonstrated
that 28-day mortality was significantly lower in the sta-
tin group compared with the no statin group (33% vs.
53%; p = 0.03).
We observed a mortality reduction with simvastatin
but not atorvastatin. A similar finding was noted by
Christensen et al. [19]. Thisr e s u l tm i g h tb er e l a t e dt o
the higher lipophilicity of simvastatin, which enables it
to better penetrate cells [29]. However, large sample size
is required to confirm these findings.
The observed beneficial effects of statins on diabetic
patients, patients with chronic cardiovascular disease
and those with low GCS (a surrogate for neurologic dis-
ease) are consistent with its reported benefits in acute
myocardial infarction and acute stroke [30,31]. Our
results are also consistent with the findings of a popula-
tion-based study by Hackam et al., who found that statin
use in patients with atherosclerosis was associated with
a reduced risk of subsequent sepsis [32].
Our findings confirm the need for randomised, con-
trolled trials to verify the relationship between statin
therapy and the observed outcomes. Other issues still
require resolution, including the dose-effect relationship,
whether the mechanism of action is related to the pleio-
tropic or lipid-lowering effect of statins, and whether
the observed effect is a class effect or an individual sta-
tin effect [33]. We hope that the ongoing clinical trials
in patients with sepsis, septic shock, ventilator-asso-
ciated pneumonia, and influenza, as well as the trials
investigating the prevention of acute lung injury and
adult respiratory distress syndrome will help address
these questions [34-38].
The findings of our study must be interpreted in the
light of its strengths and weaknesses. The strengths
include being a nested cohort within randomised






Adjusted odds ratio (aOR)
a 95% confidence interval P-value
ICU mortality, no. (%) 19/107 (17.8) 108/656 (16.5) 0.84 (0.47 - 1.51) 0.56
Dose < 40 mg 7/47 (14.9) 108/656 (16.5) 0.67 (0.28 - 1.63) 0.43
Dose ≥ 40 mg 12/60 (20.0) 108/656 (16.5) 0.97 (0.48 - 1.99) 0.98
Hospital mortality, no. (%) 42/107 (39.3) 200/656 (30.5) 0.60 (0.36 - 0.99) 0.05
Dose < 40 mg 19/47 (40.4) 200/656 (30.5) 0.69 (0.35 - 1.40) 0.30
Dose ≥ 40 mg 23/60 (38.3) 200/656 (30.5) 0.53 (0.28 - 1.00) 0.05
Variables entered initially in the stepwise regression model including age, gender, admission category, APACHE II score, history of diabetes, creatinine, platelets,
GCS, PaO2/FiO2, and chronic cardiac, renal, and respiratory diseases.
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Adjusted odds ratio (aOR)
a 95% confidence interval P-value
Hospital mortality, no. (%) 42/107 (39.3) 200/656 (30.5) 0.60 (0.36 - 0.99) 0.05
Stratified by age, no. (%)
≤ 58 yrs 6/14 (42.9) 62/374 (16.6) 0.73 (0.19 - 2.81) 0.64
> 58 yrs 36/93 (38.7) 138/282 (49.0) 0.58 (0.35 - 0.97) 0.04
Gender, no. (%)
Male 21/63 (33.3) 126/492 (25.6) 0.56 (0.29 - 1.08) 0.08
Female 21/44 (47.7) 74/164 (45.0) 0.74 (0.35 - 1.58) 0.43
Admission category, no. (%)
Postoperative 1/4 (25.0) 19/119 (16.0) 0.75 (0.04 - 14.82) 0.85
Nonoperative 41/103 (40.0) 181/537 (34.0) 0.62 (0.34 - 1.03) 0.06
APACHE II, no. (%)
APACHE≤ 22 8/33 (24.2) 53/370 (14.3) 0.77 (0.27 - 2.21) 0.63
APACHE>22 34/74 (46.0) 147/286 (51.4) 0.54 (0.31 - 0.96) 0.03
SOFA, no. (%)
≤ 9 13/58 (22.4) 63/346 (18.2) 0.55 (0.26 - 1.17) 0.12
> 9 29/49 (59.1) 137/310 (44.2) 0.73 (0.36 - 1.48) 0.38
History of diabetes, no. (%)
Yes 31/84 (37.0) 106/209 (48.4) 0.52 (0.30 - 0.90) 0.02
No 11/23 (47.8) 94/437 (21.5) 1.31 (0.49 - 3.54) 0.59
History of cardiovascular, no. (%)
Yes 23/54 (42.6) 58/103 (56.3) 0.59 (0.3 - 1.2) 0.13
No 19/53 (35.9) 142/553 (25.7) 0.52 (0.27 - 1) 0.06
Vasopressor therapy, no. (%)
Yes 31/73 (42.5) 151/423 (35.7) 0.53 (0.29 - 0.97) 0.04
No 23/34 (67.7) 184/233 (79.0) 0.92 (0.37 - 2.25) 0.84
Sepsis, no. (%)
Yes 12/28 (43.0) 88/166 (53.0) 0.64 (0.26 - 1.58) 0.33
No 30/79 (38.0) 112/490 (23.0) 0.72 (0.41 - 1.28) 0.26
Severe sepsis and septic shock no. (%)
Yes 14/26 (53.9) 84/207 (40.6) 0.22 (0.07 - 0.66 0.007
No 28/81 (34.6) 116/449 (25.7) 0.78 (0.45 - 1.37) 0.38
Creatinine, no. (%)
≤ 100 μmol/L 4/26 (15.4) 70/351 (20.0) 0.14 (0.04 - 0.51) 0.002
> 100 μmol/L 38/81 (47.0) 130/305 (43.0) 1.01 (0.58 - 1.77) 0.96
Platelets, no. (%)
≤ 180 12/25 (48.0) 125/358 (35.0) 0.62 (0.24 - 1.62) 0.33
> 180 30/82 (36.6) 75/298 (25.2) 0.78 (0.43 - 1.42) 0.42
Bilirubin, no. (%)
≤ 16 μmol/L 10/38 (26.3) 54/212 (25.5) 0.49 (0.21 - 1.20) 0.11
>1 6μmol/L 10/22 (45.5) 73/223 (32.7) 0.67 (0.23 - 1.97) 0.47
INR, no. (%)
≤1.2 20/59 (34.0) 68/312 (21.8) 0.79 (0.40 - 1.58) 0.51
>1.2 22/48 (45.8) 132/344 (38.4) 0.53 (0.26 - 1.09) 0.09
GCS, no. (%)
≤ 9 19/50 (38.0) 114/364 (31.3) 0.34 (0.17 - 0.71) 0.004
> 9 23/57 (40.4) 86/292 (29.5) 092 (0.46 - 1.85) 0.81
Length of stay, no. (%)
≤ 5 days 4/39 (10.3) 32/192 (16.7) 0.40 (0.13 - 1.28) 0.12
> 5 days 38/68 (55.9) 168/464 (36.2) 0.63 (0.34 - 1.19) 0.16
Mechanical ventilation, no. (%)
Yes 40/92 (43.5) 183/591 (31.0) 0.66 (0.34 - 1.10) 0.11
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the limitations of our study are its monocenter nature,
its post-hoc design, and the lack of data on the duration
of statin therapy prior to ICU admission, lipid profile,
and statin side effects. Because of the observational nat-
ure of the study, there were imbalances at baseline
between the statin and non-statin groups. However, we
have adjusted for these imbalances using multivariate
analysis.
Conclusion
Our study demonstrated that statin therapy during ICU
admission was associated with lower hospital mortality,
particularly among elderly patients, diabetics, patients
with high APACHE II and low GCS, those on vasopres-
sors, and those on simvastatin. In addition, using doses
greater than 40 mg per day was associated with lower
hospital mortality. Further randomised, controlled trials
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